|
1 |
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Enthalten in Targeted oncology 19.11.2020: 1-11
|
|
|
|
2 |
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
Enthalten in Targeted oncology 10.11.2020: 1-10
|
|
|
|
3 |
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms
Enthalten in Neuroendocrinology Bd. 107, 2018, Nr. 1: 24-31
|
|
|
|
4 |
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Enthalten in Targeted oncology 21.3.2016: 1-3
|
|
|
5 |
The cathedral and the bazaar
Raymond, Eric S.. - Beijing : O'Reilly, 2001, Rev. ed.
|
|
|
|
6 |
The cathedral and the bazaar
Raymond, Eric S.. - Beijing : O'Reilly, 1999, 1. ed.
|
|
|
|
7 |
Learning GNU emacs
Cameron, Debra. - Bonn : O'Reilly, 1996, 2. ed., rev. & updated
|
|
|
|
8 |
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
Enthalten in Investigational new drugs Bd. 24, 28.1.2006, Nr. 4, date:7.2006: 311-319
|
|
|
|
9 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
Enthalten in Cancer chemotherapy and pharmacology Bd. 71, 12.3.2013, Nr. 5, date:5.2013: 1297-1307
|
|
|
|
10 |
Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis
Enthalten in Cancer chemotherapy and pharmacology Bd. 72, 24.9.2013, Nr. 6, date:12.2013: 1183-1193
|
|
Administration
